Skip to main content

Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?

Publication ,  Journal Article
Banez, LL; Gerber, L; Moul, JW; Anscher, MS; Lee, WR; Koontz, BF
Published in: J Clin Oncol
February 20, 2013

56 Background: Image-guided radiation therapy (IGRT) has been widely adopted for both definitive and post-operative prostate radiotherapy. In the postoperative setting, numerous studies of prostate bed motion have recommended tight planning margins (<10mm) if IGRT is used daily. The purpose of this analysis is to determine the effect of IGRT on the efficacy and toxicity of post-operative prostate radiotherapy. METHODS: Between 1998 and 2010, 286 patients received radiation therapy after prostatectomy at Duke. Recurrent disease following radiation therapy was defined as PSA >0.2 ng/ml and rising or initiation of salvage ADT. CTCAE v 4.0 and the RTOG/LENT late morbidity scores were used to grade acute and late toxicities. Risk for biochemical failure and late Grade 2+ GI toxicity were compared between IGRT (N = 113) and non-IGRT (N = 173) patients using multivariable adjusted Cox regression controlling for age, treatment technique (3D vs IMRT), radiation dose, androgen suppression, pathologic Gleason Score, margin status, pathologic stage, and pre-radiotherapy PSA level. RESULTS: The median margin size for patients with IGRT was 7mm (IQR 6-10mm) and 15mm (IQR 7-15mm) for those without IGRT (p < 0.001). Median follow up was 21 months (IQR 15-33 mo) for patients with IGRT and 49 months (IQR 30-73 mo) for those without IGRT (p < 0.001). On multivariate analysis, patients treated with IGRT had a greater risk of progression versus non-daily imaging (HR = 2.51, p < 0.001), as did patients who received salvage versus adjuvant radiotherapy (HR = 2.41, p = 0.005). Higher pathologic Gleason Score (HR = 1.96, p = 0.026) and pathologic stage (HR = 1.93, p = 0.003) conferred increased risk of progression, while positive margin status was protective (HR = 0.53, p = 0.002). Age, radiation dose, androgen suppression, and treatment technique did not affect biochemical outcome (p > 0.1). There were no differences in acute or late GI toxicity according to treatment technique or use of IGRT (both p > 0.1). CONCLUSIONS: The use of IGRT was associated with increased biochemical recurrence for patients receiving post-operative prostate radiotherapy. For these patients, we recommend using treatment margins of at least 10mm to address subclinical disease and organ motion.

Duke Scholars

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

February 20, 2013

Volume

31

Issue

6_suppl

Start / End Page

56

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Banez, L. L., Gerber, L., Moul, J. W., Anscher, M. S., Lee, W. R., & Koontz, B. F. (2013). Image guidance for post-prostatectomy radiotherapy: Are we missing the mark? J Clin Oncol, 31(6_suppl), 56. https://doi.org/10.1200/jco.2013.31.6_suppl.56
Banez, L. L., L. Gerber, J. W. Moul, M. S. Anscher, W. R. Lee, and B. F. Koontz. “Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?J Clin Oncol 31, no. 6_suppl (February 20, 2013): 56. https://doi.org/10.1200/jco.2013.31.6_suppl.56.
Banez LL, Gerber L, Moul JW, Anscher MS, Lee WR, Koontz BF. Image guidance for post-prostatectomy radiotherapy: Are we missing the mark? J Clin Oncol. 2013 Feb 20;31(6_suppl):56.
Banez, L. L., et al. “Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?J Clin Oncol, vol. 31, no. 6_suppl, Feb. 2013, p. 56. Pubmed, doi:10.1200/jco.2013.31.6_suppl.56.
Banez LL, Gerber L, Moul JW, Anscher MS, Lee WR, Koontz BF. Image guidance for post-prostatectomy radiotherapy: Are we missing the mark? J Clin Oncol. 2013 Feb 20;31(6_suppl):56.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

February 20, 2013

Volume

31

Issue

6_suppl

Start / End Page

56

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences